Cargando…
Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment
Hemolytic uremic syndrome is defined by the characteristic triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. In children, most cases of HUS are caused by Shiga-toxin-producing bacteria, especially Escherichia coli O157:H7. Common vehicles of transmission include...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159990/ https://www.ncbi.nlm.nih.gov/pubmed/21876803 http://dx.doi.org/10.4061/2011/908407 |
_version_ | 1782210506527866880 |
---|---|
author | Boyer, Olivia Niaudet, Patrick |
author_facet | Boyer, Olivia Niaudet, Patrick |
author_sort | Boyer, Olivia |
collection | PubMed |
description | Hemolytic uremic syndrome is defined by the characteristic triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. In children, most cases of HUS are caused by Shiga-toxin-producing bacteria, especially Escherichia coli O157:H7. Common vehicles of transmission include ground beef, unpasteurized milk, and municipal or swimming water. Shiga-toxin-associated HUS is a main cause of acute renal failure in young children. Management remains supportive as there is at present no specific therapy to ameliorate the prognosis. Immediate outcome is most often favourable but long-term renal sequelae are frequent due to nephron loss. Atypical HUS represents 5% of cases. In the past 15 years, mutations in complement regulators of the alternative pathway have been identified in almost 60% of cases, leading to excessive complement activation. The disease has a relapsing course and more than half of the patients either die or progress to end-stage renal failure. Recurrence after renal transplantation is frequent. |
format | Online Article Text |
id | pubmed-3159990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | SAGE-Hindawi Access to Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-31599902011-08-29 Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment Boyer, Olivia Niaudet, Patrick Int J Nephrol Review Article Hemolytic uremic syndrome is defined by the characteristic triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. In children, most cases of HUS are caused by Shiga-toxin-producing bacteria, especially Escherichia coli O157:H7. Common vehicles of transmission include ground beef, unpasteurized milk, and municipal or swimming water. Shiga-toxin-associated HUS is a main cause of acute renal failure in young children. Management remains supportive as there is at present no specific therapy to ameliorate the prognosis. Immediate outcome is most often favourable but long-term renal sequelae are frequent due to nephron loss. Atypical HUS represents 5% of cases. In the past 15 years, mutations in complement regulators of the alternative pathway have been identified in almost 60% of cases, leading to excessive complement activation. The disease has a relapsing course and more than half of the patients either die or progress to end-stage renal failure. Recurrence after renal transplantation is frequent. SAGE-Hindawi Access to Research 2011 2011-08-17 /pmc/articles/PMC3159990/ /pubmed/21876803 http://dx.doi.org/10.4061/2011/908407 Text en Copyright © 2011 O. Boyer and P. Niaudet. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Boyer, Olivia Niaudet, Patrick Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment |
title | Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment |
title_full | Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment |
title_fullStr | Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment |
title_full_unstemmed | Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment |
title_short | Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment |
title_sort | hemolytic uremic syndrome: new developments in pathogenesis and treatment |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159990/ https://www.ncbi.nlm.nih.gov/pubmed/21876803 http://dx.doi.org/10.4061/2011/908407 |
work_keys_str_mv | AT boyerolivia hemolyticuremicsyndromenewdevelopmentsinpathogenesisandtreatment AT niaudetpatrick hemolyticuremicsyndromenewdevelopmentsinpathogenesisandtreatment |